Daraxonrasib: what the 61-patient trial, Phase 3 and FDA approval each show
A 61-patient trial found undetectable tumours in about one in 12 patients. A Phase 3 trial nearly doubled survival. The FDA approved daraxonrasib in August 2...
Daraxonrasib, a daily pill also marketed as Rasonque, has moved from an early combination trial to a Phase 3 survival result to FDA approval. The evidence for each step is different in size and strength, and the three are often collapsed into a single headline.
The earliest signal comes from a 61-patient trial of daraxonrasib plus chemotherapy in advanced pancreatic cancer. Tumours shrank or disappeared in 60.7% of patients on the combination, and 8.2% — roughly one in 12 — had no detectable tumour. The drug targets mutated KRAS, a driver present in more than nine in ten pancreatic tumours. That is a response signal from a small study, not proof of a survival benefit.
The stronger survival evidence comes from a separate Phase 3 trial in patients with previously treated metastatic pancreatic ductal adenocarcinoma. There, daraxonrasib nearly doubled overall survival compared with standard chemotherapy: about 13 months versus just over 6 months. Phase 3 randomisation is what regulators weigh most heavily, and it is the basis for the approval.
Response outcomes in 61‑patient daraxonrasib plus chemotherapy trial
In the 61‑patient trial, 60.7% of patients had tumours shrink or disappear, and 8.2% had no detectable tumour.
The FDA approved Rasonque (daraxonrasib) on August 26, 2026, for pancreatic adenocarcinoma, the most common form of the disease. The drug had earlier received orphan drug designation for pancreatic cancer, a status designed to encourage development in rare or underserved cancers.
What remains unproven is how durable the undetectable-tumour responses are in the 61-patient trial, and how the early combination results compare with the Phase 3 population.
Pancreatic cancer remains one of the deadliest cancers, which is why a KRAS-targeted pill with a Phase 3 survival gain and an approval is a genuine shift in the treatment conversation. Further trials will determine how far the early response signal extends.
Sources
- [1]lbc.co.uk
- [2]pbs.org
- [3]healthline.com
- [4]targetedonc.com
More from Science & Climate
Conversation
Reader notes
Loading comments...